Danske Bank A S Lowers Stock Holdings in Lantheus Holdings, Inc. $LNTH

Danske Bank A S lowered its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 92.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 600 shares of the medical equipment provider’s stock after selling 6,965 shares during the period. Danske Bank A S’s holdings in Lantheus were worth $40,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. Osterweis Capital Management Inc. acquired a new position in Lantheus in the 2nd quarter valued at $36,000. Hantz Financial Services Inc. lifted its stake in shares of Lantheus by 412.5% in the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 396 shares during the period. First Horizon Corp acquired a new stake in shares of Lantheus in the 3rd quarter worth $26,000. Farther Finance Advisors LLC boosted its holdings in shares of Lantheus by 71.4% in the fourth quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 275 shares in the last quarter. Finally, Blue Trust Inc. boosted its holdings in shares of Lantheus by 30.3% in the fourth quarter. Blue Trust Inc. now owns 990 shares of the medical equipment provider’s stock valued at $66,000 after acquiring an additional 230 shares in the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus News Roundup

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: Lantheus reported first-quarter EPS of $1.46, beating estimates of $1.25, on revenue of $377.3 million, also above expectations. The beat suggests solid underlying demand and execution. Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: The company issued FY2026 EPS guidance of $5.00 to $5.25, slightly above the consensus estimate, reinforcing expectations for continued profitability. Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Citizens JMP raised its price target to $115 from $85 and reiterated a Market Outperform rating, implying meaningful upside from current levels. Tickerreport.com
• Positive Sentiment: Mizuho also lifted its price target to $100 from $95 and kept an Outperform rating, adding to the bullish post-earnings analyst momentum. Benzinga
• Neutral Sentiment: Several follow-up stories highlighted valuation and the earnings call transcript, but these were mainly commentary on the already-reported results rather than new catalysts. Lantheus Holdings (LNTH) Valuation Check After Q1 Earnings Beat And FDA Approval Catalysts

Analysts Set New Price Targets

Several research analysts recently issued reports on LNTH shares. Wall Street Zen cut shares of Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $94.00 price objective on shares of Lantheus in a report on Thursday. JonesTrading cut Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, February 27th. William Blair reissued an “outperform” rating on shares of Lantheus in a research note on Tuesday, March 17th. Finally, Citigroup reissued an “outperform” rating on shares of Lantheus in a report on Friday. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $97.29.

Lantheus Stock Up 2.3%

Lantheus stock opened at $93.06 on Friday. Lantheus Holdings, Inc. has a fifty-two week low of $47.25 and a fifty-two week high of $94.86. The firm has a market capitalization of $6.06 billion, a price-to-earnings ratio of 22.42 and a beta of -0.08. The stock’s fifty day moving average is $79.69 and its two-hundred day moving average is $68.87. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.51 and a current ratio of 2.83.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.25 by $0.21. The business had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The business’s revenue was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.53 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Analysts predict that Lantheus Holdings, Inc. will post 4.26 EPS for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.